Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company''s History
Ceapro posts highest revenues, profits and cash flows reported in Company's history for both Q4 2015 and FY 2015
(firmenpresse) - EDMONTON, ALBERTA -- (Marketwired) -- 04/14/16 -- (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve-months ended December 31, 2015. The Company''s 2015 Financial Results reveal the best year in Ceapro''s history.
Financial Highlights for the Full Year 2015
"The continued year-over-year revenue performance of our high-value, de-risked base business in cosmeceuticals represents a significant achievement for Ceapro. In 2015, we delivered the best financial results, by a substantial margin, in Ceapro''s history for a second year in a row, underscoring the effectiveness of our business strategy and enhanced unique competitive position," Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated.
2015 Key Financial Highlights
"We are enormously proud of ending the year with these results, despite a challenging economic environment, and credit it to our remarkable team who continues to rise to the challenge, the strength of our highly innovative projects and our gradual expansion into personal care markets worldwide," added Mr. Gagnon. "The success of our two pharmaceutical grade active ingredients, beta glucan and avenanthramides, affords us the opportunity to expand development into nutraceutical and pharmaceutical formulations and brings us another step closer to advance our long-term strategic vision and unlock shareholder value in both the near and long-term."
Financial Results for Twelve Month Period Ended December 31, 2015
The complete financial statements are available for review on SEDAR at and on the Company''s website at .
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company''s website at .
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
Jenene Thomas Communications, LLC
T (US): 908-938-1475
E:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.04.2016 - 05:35 Uhr
Sprache: Deutsch
News-ID 1428063
Anzahl Zeichen: 3075
contact information:
Contact person:
Town:
EDMONTON, ALBERTA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company''s History
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ceapro Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
